Coronary Interventions and Diagnostics

A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa895

• DURMUŞ ERALP TUTAR

Guidelines on myocardial revascularization

• ENVER ATALAR

No abstract yet.

• MÜRSEL ŞAHİN

BACKGROUND: Triple antithrombotic therapy with warfarin plus two antiplatelet agents is the standard of care after percutaneous coronary intervention (PCI) for patients with atrial fibrillation, but this therapy is associated with a high risk of bleeding. METHODS: inhibitor (clopidogrel or ticagrelor) and no aspirin (…

• ABDURRAHMAN OĞUZHAN

BACKGROUND: Coronary revascularization guided by fractional flow reserve (FFR) is associated with better patient outcomes after the procedure than revascularization guided by angiography alone. It is unknown whether the instantaneous wave-free ratio (iFR), an alternative measure that does not require the administratio…

BACKGROUND: Although myocardial ischemia is known to be significantly related to the development of coronary collateral vessels (CCVs), there is considerable variation between patients with ischemic heart disease in the presence of collateral development. The nature of this variability is not well known. Likewise, it…

BACKGROUND: Although myocardial ischemia is known to be significantly related to the development of coronary collateral vessels (CCVs), there is considerable variation between patients with ischemic heart disease in the presence of collateral development. The nature of this variability is not well known. Likewise, it…

• ADNAN ABACI

No abstract yet.

• ÖZGÜR BAYTURAN

Lamy, André*; Devereaux, P.J.*; Prabhakaran, Dorairaj†; Taggart, David P.‡; Hu, Shengshou§; Paolasso, Ernesto∥; Straka, Zbynek¶; Piegas, Leopoldo S.#; Akar, Ahmet Ruchan**; Jain, Anil R.††; Noiseux, Nicolas‡‡; Padmanabhan, Chandrasekar§§; Bahamondes, Juan-Carlos∥∥; Novick, Richard J.¶¶; Vaijyanath, Prashant##; Reddy,…

• AHMET RÜÇHAN AKAR

No abstract yet.

BACKGROUND: The first clinical study of paclitaxel-eluting stent for de novo lesions showed promising results. We performed the TAXUS III trial to evaluate the feasibility and safety of paclitaxel-eluting stent for the treatment of in-stent restenosis (ISR). METHODS AND RESULTS: The TAXUS III trial was a single-arm, 2…

No abstract yet.

• ABDURRAHMAN KAMURAN KADIPAŞAOĞLU